Literature DB >> 16005216

The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion.

Roger L Papke1, Guangrong Zheng, Nicole A Horenstein, Linda P Dwoskin, Peter A Crooks.   

Abstract

The alpha7 nAChR subtype is of particular interest as a potential therapeutic target since it has been implicated as a mediator of both cognitive and neuroprotective activity. The rigid nicotine analog ACME and the N-cyanoborane conjugate ACME-B are selective partial agonists of rat alpha7 receptors expressed in Xenopus oocytes, with no significant activation of either alpha3beta4 or alpha4beta2 receptors. ACME-B is both more potent and efficacious than ACME. The efficacies of ACME-B and ACME are approximately 26% and 10% of the efficacy of ACh, respectively. Similar N-conjugation of S(-)nicotine with cyanoborane decreased efficacy for alpha3beta4 and alpha4beta2 receptors, as well as for alpha7 nAChR. Structural comparison of ACME with the benzylidene anabaseines, another class of previously identified alpha7-selective agonists, suggests that they share a similar structural motif that may be applicable to other alpha7-selective agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005216      PMCID: PMC3593044          DOI: 10.1016/j.bmcl.2005.05.118

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

Review 1.  Neuronal nicotinic receptors, important new players in brain function.

Authors:  F Clementi; D Fornasari; C Gotti
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

2.  Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.

Authors:  R L Papke; Julia K Porter Papke; G M Rose
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

Review 3.  Musings on alpha4beta2 nicotinic acetylcholine (nACh) receptor pharmacophore models.

Authors:  Richard A Glennon; Malgorzata Dukat; Liang Liao
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

4.  Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors.

Authors:  E M Meyer; A Kuryatov; V Gerzanich; J Lindstrom; R L Papke
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

5.  Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family.

Authors:  J Boulter; J Connolly; E Deneris; D Goldman; S Heinemann; J Patrick
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Molecular dissection of tropisetron, an alpha7 nicotinic acetylcholine receptor-selective partial agonist.

Authors:  Roger L Papke; Hillary C Schiff; Brian A Jack; Nicole A Horenstein
Journal:  Neurosci Lett       Date:  2005-01-05       Impact factor: 3.046

7.  Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies.

Authors:  P J Whiting; J M Lindstrom
Journal:  J Neurosci       Date:  1988-09       Impact factor: 6.167

Review 8.  Schizophrenia, sensory gating, and nicotinic receptors.

Authors:  L E Adler; A Olincy; M Waldo; J G Harris; J Griffith; K Stevens; K Flach; H Nagamoto; P Bickford; S Leonard; R Freedman
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

9.  A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.

Authors:  C M Flores; S W Rogers; L A Pabreza; B B Wolfe; K J Kellar
Journal:  Mol Pharmacol       Date:  1992-01       Impact factor: 4.436

10.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

View more
  8 in total

1.  First-principles calculation of pKa for cocaine, nicotine, neurotransmitters, and anilines in aqueous solution.

Authors:  Haiting Lu; Xi Chen; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2007-08-11       Impact factor: 2.991

2.  Tying up Nicotine: New Selective Competitive Antagonist of the Neuronal Nicotinic Acetylcholine Receptors.

Authors:  Ida Nymann Petersen; François Crestey; Anders A Jensen; Dinesh C Indurthi; Henrik Pedersen; Jesper T Andreasen; Thomas Balle; Jesper L Kristensen
Journal:  ACS Med Chem Lett       Date:  2015-03-04       Impact factor: 4.345

3.  Expeditious synthesis of cis-1-methyl-2, 3,3a,4,5,9b-hexahydro-1H-pyrrolo-[3,2h]isoquinoline / [2,3-f]quinoline via azomethine ylide-alkene [3+2] cycloaddition.

Authors:  Zhenfa Zhang; Linda P Dwoskin; Peter A Crooks
Journal:  Tetrahedron Lett       Date:  2011-05-25       Impact factor: 2.415

Review 4.  High throughput electrophysiology with Xenopus oocytes.

Authors:  Roger L Papke; Cathy Smith-Maxwell
Journal:  Comb Chem High Throughput Screen       Date:  2009-01       Impact factor: 1.339

5.  Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.

Authors:  Nicole A Horenstein; Fedra M Leonik; Roger L Papke
Journal:  Mol Pharmacol       Date:  2008-09-02       Impact factor: 4.436

6.  Activation of cholinergic anti-inflammatory pathway involved in therapeutic actions of α-mangostin on lipopolysaccharide-induced acute lung injury in rats.

Authors:  Zhe Yang; Qin Yin; Opeyemi Joshua Olatunji; Yan Li; Shu Pan; Dan-Dan Wang; Jian Zuo
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

Review 7.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

Review 8.  Synthetic Methods for the Preparation of Conformationally Restricted Analogues of Nicotine.

Authors:  Biswajit Panda; Gianluigi Albano
Journal:  Molecules       Date:  2021-12-13       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.